Development of treatment options for Chinese patients with advanced squamous cell lung cancer: focus on afatinib.

77 A subgroup analysis conducted to assess outcomes in 89 East Asian patients, 35% of whom had SqCC of the lung, showed a trend for clinical benefit favoring the ramucirumab-containing regimen. 78 Due to the increased incidence of neutropenia and febrile neutropenia observed in East Asian patients, the starting dose of docetaxel was amended and reduced in 24 patients enrolled later into the trial. 77 , 78 Serious AEs related to the mechanism of action of ramucirumab include hemorrhage, GI perforation, and impaired wound healing. 15 As with immune checkpoint inhibitors, infusion-related reactions can occur with IV administration of anti-VEGFR inhibitors, so similar precautions and pre-medications are required.

also in 53,322 other papers